Group 1 - The core viewpoint of the news is that China Resources Double Crane plans to establish a 500 million RMB biopharmaceutical industry fund focusing on synthetic biology [1][2] - The fund aims to optimize the company's layout in key areas such as synthetic biology, promote innovation incubation, accelerate product and technology collaboration, and acquire commercialization rights [2] - The fund has a duration of 8 years, including a 4-year investment period and a 4-year management exit period, with a possible 1-year extension [2] Group 2 - The company will contribute up to 87 million RMB, accounting for no more than 17.40% of the total fund contribution [1] - The fund is currently in the preparation stage and requires completion of partner recruitment, business registration, and filing with the China Securities Investment Fund Industry Association before it can officially operate [2] - The fund sets an annualized threshold return of 8% and adopts a market-oriented exit mechanism [2]

Group 1 - China Resources Pharmaceutical (03320) announced a collaboration to establish a fund with an expected scale of RMB 500 million [1] - The fund is anticipated to focus on high-growth investments in synthetic biology, innovative drugs, and biotechnology sectors [1] - The company plans to commit a total investment of up to RMB 123 million, representing approximately 24.6% of the total committed capital for the fund [1] Group 2 - The fund is expected not to be accounted as a subsidiary of the company after its establishment [1] - Shenzhen China Resources Capital is expected to be appointed as the fund manager [1]

Core Viewpoint - China Resources Double Crane (华润双鹤) is strategically investing in synthetic biology, establishing a biopharmaceutical industry fund with a target of 500 million RMB to enhance its investment capabilities in key areas like synthetic biology and health products [2][4]. Group 1: Investment and Strategic Direction - On August 12, China Resources Double Crane announced plans to establish a biopharmaceutical industry fund with a target fundraising scale of 500 million RMB, with the company and its wholly-owned subsidiary contributing up to 87 million RMB, accounting for no more than 17.4% of the total fund [2]. - The company has identified synthetic biology as one of its strategic development directions and has established a comprehensive "R&D + pilot test + industrialization" three-tier system, including a synthetic biology industrialization platform in Hohhot [2][4]. - The establishment of the fund aims to optimize the company's strategic layout in synthetic biology and other key areas, leveraging synergies with Hohhot's industrial development to enhance investment methods in synthetic biology [2]. Group 2: Financial Performance - In the first quarter of 2025, China Resources Double Crane achieved revenue of 3.079 billion RMB and a net profit attributable to shareholders of 507 million RMB [3]. Group 3: Historical Context and Acquisitions - In 2022, China Resources Double Crane invested 500 million RMB to acquire Shenzhou Biology, establishing it as a base for synthetic biology industrialization [4]. - In 2023, the company established the China Resources Double Crane Synthetic Biology Research Institute, focusing on talent acquisition and the simultaneous construction of a pilot test base [4]. Group 4: Technological Development - The small-scale testing platform has been largely completed, focusing on core capabilities such as molecular modification, high-throughput screening, strain validation, and enzyme engineering [6]. - The company is prioritizing the construction of pilot fermentation workshops to enhance its pilot conversion capabilities [6]. Group 5: Market Positioning - Shenzhou Biology is recognized as the world's second-largest supplier of coenzyme Q10, holding a stable global market share of 30% [7]. - The chairman of the company emphasized that the focus on synthetic biology is primarily around health products, aiming to enhance the competitiveness of existing core products through synthetic biology technology [7].

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-065 华润双鹤药业股份有限公司 关于设立华润双鹤产业基金暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 重要内容提示： 交易简要内容：华润双鹤药业股份有限公司(以下简称"华润 双鹤"或"公司")拟投资设立华润双鹤生物医药产业基金(呼和浩特) 投资合伙企业(有限合伙)(暂定名，以工商核准名为准，以下简称"华 润双鹤产业基金"或"该基金")，基金目标募集规模为 5 亿元人民 币，公司及全资子公司双鹤(北京)生物技术有限公司(以下简称"双鹤 生物")拟以自有资金出资不超过 8,700 万元人民币，占基金总出资额 的比例不超过 17.40%。 本次交易构成关联交易，不构成重大资产重组。 2 本次交易金额超过 3,000 万元，未超过公司 2024 年度经审计 净资产的 5%，已经董事会审议批准，无需提交股东会审议。 过去 12 个月内，除日常关联交易及本次交易外，公司拟以自 有资金 4,000 万元人民币与华润医药投资有限公司等 11 家合伙人共 ...

Core Viewpoint - The company has received approval for its amino acid (15) peritoneal dialysis solution, which will enhance its product line and market competitiveness [1][4]. Group 1: Drug Approval and Details - The company’s wholly-owned subsidiary, Shanghai Changfu, received the Drug Supplement Application Approval Notice from the National Medical Products Administration for the amino acid (15) peritoneal dialysis solution [1]. - This drug is designed for chronic renal failure patients, particularly those with serum albumin levels below 35g/L, and does not contain glucose [1]. Group 2: Market Situation of Similar Drugs - The amino acid (15) peritoneal dialysis solution is developed by Baxter and is marketed as "NUTRINEAL" in several countries, with a global sales figure of $21.3 million in 2024 [3]. - In China, three companies, including Shanghai Changfu, have approved the amino acid (15) peritoneal dialysis solution, with a total sales figure of 22.54 million yuan in 2024 [3]. - The market shares of the top three companies in the domestic market are as follows: Chengdu Qingshan Likang Pharmaceutical at 77.88%, Shandong Weigao Pharmaceutical at 14.04%, and Tianjin Tianyao at 8.08% [3]. Group 3: R&D Investment - The company has invested a total of 9.5 million yuan in the research and development of this drug, including technology transfer [2].

一、通知书主要内容 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－064 华润双鹤药业股份有限公司 关于全资子公司上海长征富民金山制药有限公司 氨基酸(15)腹膜透析液获得药品补充申请批准通知书的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公 司上海长征富民金山制药有限公司(以下简称"上海长富")收到了国 家药品监督管理局(以下简称"国家药监局")颁发的氨基酸(15)腹膜 透析液(以下简称"该药品")《药品补充申请批准通知书》(编号： 2025B03434)。现将相关情况公告如下： 截至本公告日，公司针对该药品累计研发投入(含药品技术转让) 为人民币 950 万元(未经审计)。 三、同类药品的市场状况 氨基酸(15)腹膜透析液由百特公司研制开发，目前已在英国、德 国、法国、意大利等国家获批上市，商品名为"NUTRINEAL"，原 研药品未在中国上市。根据全球71国家药品销售数据库显示，2024 年"NUTRINEAL"的销售额为2.13 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－063 华润双鹤药业股份有限公司 关于全资孙公司北京双鹤润创科技有限公司 DC50292A片获得美国FDA临床试验许可的公告 3、申请人：北京双鹤润创科技有限公司 4、结论：同意该药品在美国进行临床试验 二、药品相关情况 DC50292A片拟用于治疗晚期实体瘤患者。 该药品已经获得国家药品监督管理局颁发的《药物临床试验批准 通知书》，详见公司于2025年2月17日在上海证券交易所网站 www.sse.com.cn披露的《关于全资孙公司北京双鹤润创科技有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资孙公司 北京双鹤润创科技有限公司收到了美国FDA(即"美国食品药品监督 管理局")关于同意DC50292A片(以下简称"该药品")进行临床试验的 函告(IND编号：175068)。现将相关情况公告如下： 一、函告主要内容 1、药品名称：DC50292A片 2、剂型：片剂 由于医药产品的前期研发以及产品从 ...

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., received FDA approval for clinical trials of DC50292A tablets, which are intended for the treatment of advanced solid tumors [1] Summary by Categories Company Development - The cumulative R&D investment for the drug DC50292A amounts to RMB 41.66 million [1] - The drug is currently in the early stages of clinical development, indicating significant uncertainty [1] Industry Context - The approval from the FDA marks a critical step in the drug development process, potentially positioning the company within the competitive oncology market [1]

Core Viewpoint - The legal opinion letter issued by Beijing Zhonglun Law Firm confirms the compliance and authorization of China Resources Double Crane Pharmaceutical Co., Ltd.'s stock repurchase and cancellation plan for part of its restricted stock incentive program [1][2][3] Group 1: Approval and Authorization - The company has obtained necessary approvals and authorizations for the stock repurchase and cancellation, in accordance with relevant regulations and the incentive plan [4][5] - The legal opinion is based on a thorough review of the company's incentive plan and related documents, ensuring compliance with the Company Law and Securities Law [2][3] Group 2: Repurchase Plan Details - The repurchase is due to specific circumstances where certain incentive recipients no longer meet the conditions for holding restricted stock, resulting in a total of 79,013 shares to be repurchased [4][5] - The repurchase price for the shares is set at 6.125 yuan per share for certain recipients and 10.004 yuan per share for others, with adjustments based on market conditions and company performance [6][7] Group 3: Implementation Status - The company has followed the necessary procedures to notify creditors regarding the reduction of registered capital due to the stock repurchase [8] - The repurchase of the shares is expected to be completed by July 30, 2025, with subsequent legal and registration processes to be carried out [8]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－062 华润双鹤药业股份有限公司 关于 2021 年限制性股票激励计划回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 重要内容提示： 回购注销的原因：鉴于华润双鹤药业股份有限公司(以下简称 "公司")2021 年限制性股票激励计划中 7 名激励对象已不符合激励 条件，公司回购注销前述激励对象已获授但尚未解除限售的限制性 股票共计 79,013 股。 本次注销股份的有关情况： | 回购股份数量(股) | 注销股份数量(股) | 注销日期 | | --- | --- | --- | | 79,013 | 79,013 | 2025年7月30日 | 一、本次限制性股票回购注销的决策与信息披露 (一)公司于 2025 年 3 月 18 日召开第十届董事会第九次会议、第 十届监事会第八次会议审议通过《关于回购注销部分激励对象已获 授但尚未解除限售的限制性股票的议案》。具体内容详见公司于 2025 年 3 月 20 日披露的《关于公司 2021 年限制 ...